HealthcareServices

Global Glaucoma Market Set for Strong Expansion, Reaching $10.62 Billion With 5.3% CAGR by 2030

February 27, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the glaucoma market from 2026–2035 with trusted insights from The Business Research Company

What total market size is anticipated for the Glaucoma Market in 2030?

The glaucoma market has experienced strong growth in recent years. It is anticipated to expand from $8.2 billion in 2025 to $8.65 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 5.5%. The historic growth can be linked to factors such as an aging population, increased eye disease prevalence, advancements in ophthalmic diagnostics, early drug therapy adoption, and the growth of eye clinics.

The glaucoma market is projected to experience substantial expansion in the coming years, with its size set to reach $10.62 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 5.3%. This growth during the forecast period is primarily driven by technological advancements in imaging, an increase in surgical innovations, the implementation of digital eye health monitoring, various early detection initiatives, and rising investments in ophthalmology. Significant trends expected during this period include a greater adoption of early diagnostic screening, enhanced utilization of combination drug therapies, the expansion of minimally invasive glaucoma surgery, increased availability of home-based eye monitoring, and improved patient awareness programs.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20820&type=smp

What Drivers Are Influencing Production Trends In The Glaucoma Market?

The increasing occurrence of chronic eye conditions is anticipated to fuel the expansion of the glaucoma market in the future. These conditions are defined as enduring ailments impacting the eyes, frequently resulting in lasting vision issues or unease, necessitating continuous care or therapy. The increase in chronic eye conditions can be attributed to an aging global demographic, extended periods of screen usage, specific lifestyle choices, and a greater incidence of co-existing conditions such as diabetes and hypertension. Treatment for glaucoma becomes essential in chronic eye conditions to reduce intraocular pressure, avert additional damage to the optic nerve, and safeguard vision, considering that unaddressed glaucoma may result in permanent blindness. As an illustration, figures from December 2024, released by the National Health Service (NHS), a public healthcare system in the UK, indicate that more than 2 million individuals in the UK are experiencing sight loss as of 2024. Furthermore, projections suggest that the population affected by sight loss will rise by 27%, reaching roughly 2.8 million by the year 2035. Consequently, the growing incidence of chronic eye conditions is a key driver for the glaucoma market.

Which Segment Groups Are Influencing The Glaucoma Market?

The glaucoma market covered in this report is segmented –

1) By Disease Type: Open Angle Glaucoma, Angle Closure Glaucoma, Other Disease Types

2) By Diagnosis: Tonometry, Ophthalmoscopy, Perimetry, Gonioscopy

3) By Drug Class: Beta Blockers, Prostaglandins, Alpha Adrenergic Agonist, Carbonic Anhydrase Inhibitors, Combination Drugs, Other Drug Classes

4) By Administration: Oral, Injections, Intravitreal, Other Administrations

5) By End-User: Hospitals, Ophthalmic Clinics, Ambulatory Surgical Centers

Subsegments:

1) By Open Angle Glaucoma: Primary Open Angle Glaucoma (POAG), Secondary Open Angle Glaucoma

2) By Angle Closure Glaucoma: Primary Angle Closure Glaucoma, Secondary Angle Closure Glaucoma

3) By Other Disease Types: Normal-Tension Glaucoma, Pigmentary Glaucoma, Pseudoexfoliative Glaucoma, Congenital Glaucoma

What Trends Are Expected To Impact The Competitive Landscape Of The Glaucoma Market?

Major companies within the glaucoma market are concentrating on the creation of advanced treatments, such as Rho-kinase (ROCK) inhibitors. These inhibitors offer a dual mechanism of action, which involves both improving the outflow of aqueous humor and relaxing trabecular meshwork cells, thereby effectively lowering intraocular pressure and treating glaucoma. Rho-kinase (ROCK) inhibitors are a group of medications designed to specifically target and inhibit the function of Rho-kinase enzymes, which are responsible for regulating cell contraction and are used to treat glaucoma by reducing intraocular pressure. An illustration of this trend is Santen Pharmaceutical Co. Ltd., a Japan-based eye care products firm, which introduced Roclanda in the UK in July 2023. Roclanda is a fixed-dose combination (FDC) medication comprising latanoprost and netarsudil, with the latter being a new Rho-kinase (ROCK) inhibitor. This combination effectively lowers intraocular pressure (IOP) by addressing trabecular meshwork dysfunction. It is prescribed for adult patients suffering from primary open-angle glaucoma or ocular hypertension whose IOP has not been sufficiently reduced by monotherapy with a prostaglandin or netarsudil. The launch of Roclanda in Europe represents the first new category of glaucoma medication in 25 years, marking a significant advancement in treatment. By merging netarsudil and latanoprost, Roclanda functions synergistically to enhance outflow through both the conventional (trabecular) and unconventional (uveoscleral) pathways, providing a comprehensive strategy for managing elevated IOP.

Who Are The Core Companies Influencing Trends In The Glaucoma Market?

Major companies operating in the glaucoma market are Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Teva Pharmaceuticals Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Ltd., Cipla Limited, Bausch & Lomb Corp., Carl Zeiss Meditec, Santen Pharmaceuticals Co. Ltd., Topcon Corporation, Thea Laboratoires, Corza Ophthalmology, Lumenis Ltd., Alcon Inc., Glaukos Corporation, Iridex Corporation, Nova Eye Medical Ltd., Nidek Co. Ltd., Haag-Streit AG

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/glaucoma-global-market-report

Which Region Is Expected To Experience The Fastest Growth In The Glaucoma Market?

North America was the largest region in the glaucoma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glaucoma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Glaucoma Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20820&type=smp

Browse Through More Reports Similar to the Global Glaucoma Market 2026, By The Business Research Company

Optic Atrophy Management Market Report 2026

https://www.thebusinessresearchcompany.com/report/optic-atrophy-management-global-market-report

Minimally Invasive Glaucoma Surgery Migs Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/minimally-invasive-glaucoma-surgery-migs-devices-global-market-report

Eye Melanoma Market Report 2026

https://www.thebusinessresearchcompany.com/report/eye-melanoma-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795